MARKET

EYEG

EYEG

EyeGate Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.730
-0.020
-0.53%
After Hours: 3.970 +0.24 +6.43% 18:32 10/19 EDT
OPEN
3.760
PREV CLOSE
3.750
HIGH
3.760
LOW
3.620
VOLUME
38.88K
TURNOVER
--
52 WEEK HIGH
12.89
52 WEEK LOW
2.850
MARKET CAP
17.26M
P/E (TTM)
-1.3950
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
EYEG: Raising Target on positive pipeline progress
By Beth Senko, CFA NASDAQ:EYEG READ THE FULL EYEG RESEARCH REPORT We are raising our target valuation for EyeGate Pharmaceuticals (NASDAQ:EYEG) from $12.00 to $15.00 based on solid progress in its existing pipeline and the introduction of a new candidate for treating bacterial conjunctivitis. Since early
Zacks Small Cap Research · 09/28 15:05
How Much Does EyeGate Pharmaceuticals' (NASDAQ:EYEG) CEO Make?
Stephen From has been the CEO of EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) since 2005, and this article will examine...
Simply Wall St. · 09/25 15:48
EyeGate Pharma to Present at H.C. Wainwright 22nd Annual Global Investment Conference
WALTHAM, MA / ACCESSWIRE / September 8, 2020 / EyeGate Pharmaceuticals, Inc.
ACCESSWIRE · 09/08 11:55
Mid-Day Market Update: Nasdaq Rises 2%; Cellular Biomedicine Shares Spike Higher
Midway through trading Wednesday, the Dow traded up 0.76% to 27897.59 while the NASDAQ rose 2% to 10998.64. The S&P also rose, gaining 1.26% to 3,375.53.
Benzinga · 08/12 16:00
Cassava Sciences among healthcare gainers; Sorrento Therapeutics and Novavax among losers
Gainers: Biofrontera (BFRA) +46%. Cellular Biomedicine (CBMG) +35%. The Pennant (PNTG) +30%. Cassava Sciences (SAVA) +25%. EyeGate Pharmaceuticals (EYEG) +23%.Losers: Sorrento Therapeutics (SRNE) -20%. Novavax (NVAX) -19%. Heat Biologics (HTBX) -17%. Trevena (TRVN) -16%. Vaxart (VXRT) -15%.
Seekingalpha · 08/12 15:03
Mid-Morning Market Update: Markets Open Higher; Brinker Reports Mixed Q4 Results
Following the market opening Wednesday, the Dow traded up 0.82% to 27916.32 while the NASDAQ rose 1.64% to 10959.59. The S&P also rose, gaining 1.16% to 3,372.49.
Benzinga · 08/12 14:20
Eyegate Pharmaceuticals shares are trading higher after the company announced it has received positive feedback following its pre-IND meeting with the FDA and has been provided a path forward for the development of MoxiGel, a combination product for the treatment of bacterial conjunctivitis.
Benzinga · 08/12 11:10
EyeGate Pharma Confirms Path Forward With FDA To Develop MoxiGel Combination Product; Says Has Received Positive Feedback Following Pre-IND Meeting
WALTHAM, MA / ACCESSWIRE / August 12, 2020 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company"), a clinical-stage company focused on developing products for treating
Benzinga · 08/12 10:58
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EYEG. Analyze the recent business situations of EyeGate Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EYEG stock price target is 10.75 with a high estimate of 12.00 and a low estimate of 9.50.
EPS
Institutional Holdings
Institutions: 26
Institutional Holdings: 1.98M
% Owned: 42.81%
Shares Outstanding: 4.63M
TypeInstitutionsShares
Increased
3
1.75K
New
6
-4.51K
Decreased
1
246
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.67%
Pharmaceuticals & Medical Research
-1.70%
Key Executives
Chairman/Independent Director
Paul Chaney
President/Chief Executive Officer/Director
Stephen From
Chief Financial Officer
Sarah Romano
Vice President
Michael Manzo
Director
Steven Boyd
Director
Keith Maher
Director
I. Keith Maher
Other
Mike Garanzini
Independent Director
Morton Goldberg
Independent Director
Thomas Hancock
Independent Director
Bernard Malfroy-Camine
Independent Director
Praveen Tyle
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About EYEG
Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Eyegate Pharmaceuticals Inc stock information, including NASDAQ:EYEG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EYEG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EYEG stock methods without spending real money on the virtual paper trading platform.